Tweet
1.0 SITUATION
The purpose of this document is to provide public health officials with guidance on the management of human exposures to avian influenza in birds or animals or suspected human cases of avian influenza, notably highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5N1 or H5N2 reassortment viruses.
The guidance is based on the Human Health Issues related to Avian Influenza in Canada1 and updated to reflect guidance on the current circulating strains. This guidance will be modified and updated as the situation or the virus evolves.
1.0 SITUATION .................................................. .................................................. .............. 2
2.0 BACKGROUND.................................................. .................................................. ........ 2
3.0 IMPACT OF AVIAN INFLUENZA ON HUMAN HEALTH ............................................... 3
3.1 Human Case Definitions .................................................. .......................................... 4
3.2 Transmission to the Human Population .................................................. .................... 4
3.3 Incubation Period............................................ .................................................. ......... 5
3.4 Communicability .................................................. .................................................. .... 5
3.5 Communicable Period in Human Cases .................................................. ................... 5
3.6 Signs and Symptoms .................................................. ............................................... 6
4.0 RESPONSE TO AVIAN INFLUENZA IN BIRDS AND OTHER LIVESTOCK .................. 6
5.0 MANAGEMENT OF EXPOSURE TO AN AVIAN SOURCE ........................................... 7
5.1 5.2 Human Exposure (Contact) Management........................................ ........................... 7
Management of Asymptomatic Exposed Individuals .................................................. . 8
5.3 5.5 Management of Symptomatic Exposed Individuals .................................................. ... 8
5.4 Exposure Risk Assessment........................................ ................................................ 9
Antiviral Prophylaxis and Treatment .................................................. ....................... 10
5.6 Testing .................................................. .................................................. ................ 12
5.7 Infection Control .................................................. .................................................. .. 13
5.8 5.8.1 Personal Protective Equipment .................................................. .............................. 13
PPE in a Farm Setting .................................................. .................................... 13
5.8.2 PPE in a Healthcare Setting .................................................. ............................ 14
6.0 REPORTING AND TIMELINES.................................................. ................................. 14
6.1 Animal Cases .................................................. .................................................. ...... 14
6.2 Human Cases............................................. .................................................. ........... 14
6.3 Public Education .................................................. .................................................. .. 14
7.0 REFERENCES .................................................. .................................................. ....... 16
8.0 APPENDIX 1: Self-monitoring considerations.................................................. ........ 19
Continued: http://www.bccdc.ca/resource-gallery...1-Outbreak.pdf